FLT3 and leukemia: In addition, 21 days after stopping treatment, we reevaluated leukemia burden in the bone marrow of the surviving mice and found that the shAXL mice treated with 30 mg·kg−1 of gilteritinib still had very low leukemia burden (less than 3%), highlighting that combined AXL and FLT3 inhibition has striking effects on in vivo survival (Fig. S8A).